Menu
  • Join
  • Login
  • Contact
 

Search abstracts


CASE CONTROL STUDY ABOUT THE RISK OF PANCREATIC CANCER WITH DIPEPTIDYL PEPTIDASE-4 INHIBITORS

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Presentation
  • By: MANSOUR, Maryline (Lebanese International University, Pharmaceutical, Lebanon)
  • Co-author(s): Maryline Hikmat Mansour: PharmD, Lebanese International University, Beirut, Lebanon
    Faten Awada: PharmD, Lebanese International University, Beirut, Lebanon
    Jihan Safwan: Biomedical Sciences Department , Lebanese International University, Beirut, Lebanon
    Nathalie Lahoud: PharmD, Lebanese International University, Beirut, Lebanon
    Faraj Saade: Biomedical Sciences Department, Lebanese International University, Beirut, Lebanon
    Michelle Cherfan: Biomedical Sciences Department, Lebanese International University, Beirut, Lebanon
    Marwan Akel: Pharmacy Practice, Lebanese International University, Beirut, Lebanon
    Fouad Sakr: PharmD, Lebanese International University, Beirut, Lebanon
    Mariam Dabbous: Pharmacy Practice, Lebanese International University, Beirut, Lebanon
    Mohamad Rahal: Pharmaceutical Sciences, Lebanese International University, Beirut, Lebanon
  • Abstract:

    Background

    Pancreatic cancer is one of the deadliest malignancies worldwide. Since, the risk of this disease with incretin based therapies is controversial, we conducted this study to evaluate the risk of this type of cancer with dipeptidyl peptidase-4 (DPP-4) inhibitors.

    Methods

    A retrospective case-control study was conducted among Lebanese

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses